Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Transgene and BioInvent evaluate BT-001 oncolytic virus in combination trial with KEYTRUDA.

Document Cited in Related
Vincent

NORDIC BUSINESS REPORT-October 10, 2023-Transgene and BioInvent evaluate BT-001 oncolytic virus in combination trial with KEYTRUDA

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Biotechnology companies Transgene (Euronext Paris: TNG) and BioInvent International AB (Nasdaq Stockholm: BINV) on Tuesday announced the initiation of a Phase I Part B of a clinical trial evaluating the oncolytic virus BT-001 in combination with KEYTRUDA (pembrolizumab) for treating solid tumours, including melanoma.

MSD (Merck & Co Inc, Rahway, NJ, USA) is suppling KEYTRUDA.

The trial aims to enroll a minimum of 12 patients with advanced solid tumours, assessing safety, efficacy and immune changes in the tumor microenvironment.

BT-001, co-developed by Transgene and BioInvent, utilises Transgene's Invir.IO platform, encoding BioInvent's anti-CTLA-4 antibody and human GM-CSF cytokine. The drug is currently undergoing Phase I/IIa clinical trials as a single agent and in combination with KEYTRUDA, with completion of Phase B expected in H1 2024. Previous Phase I data indicated BT-001's mechanism of action and initial anti-tumoural activity.

The ongoing multicentre trial (NCT: 04725331) is open-label and dose-escalation, divided into Part A (evaluating BT-001 as a single agent) and Part B (exploring combination therapy with KEYTRUDA). Patient inclusions are ongoing in Europe (France, Belgium) and...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT